Prime Medicine (PRME) Capital Expenditures (2021 - 2026)

Prime Medicine has reported Capital Expenditures for 6 years, with the latest figure at $214000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 91.16% year-over-year to $214000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (down 267.25% YoY), and the FY2025 full-year result was $114000.0, down 90.12% from the prior year.
• Capital Expenditures for Q1 2026 stood at $214000.0, up from -$4.1 million in the prior quarter.
• The five-year high for Capital Expenditures was $6.2 million in Q3 2023, with the low at -$4.1 million in Q4 2025.
• Historically, Capital Expenditures has averaged $657352.9 across 5 years, with a median of $895000.0 in 2022.
• The largest YoY upside for Capital Expenditures was 1777.46% in 2025 against a maximum downside of 495.69% in 2025.
• Prime Medicine's Capital Expenditures stood at $99000.0 in 2022, then jumped by 1758.59% to $1.8 million in 2023, then sank by 43.32% to $1.0 million in 2024, then slumped by 495.69% to -$4.1 million in 2025, then surged by 105.19% to $214000.0 in 2026.
• The last three Capital Expenditures figures came in at $214000.0 (Q1 2026), -$4.1 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.